The estimated Net Worth of Carmen Bozic is at least 29.7 百万$ dollars as of 7 August 2024. Carmen Bozic owns over 2,280 units of Vertex Pharmaceuticals stock worth over 11,041,978$ and over the last 5 years he sold VRTX stock worth over 18,692,785$. In addition, he makes 0$ as Executive Vice President - Global Medicines Development and Medical Affairs、 Chief Medical Officer at Vertex Pharmaceuticals.
Sign up
Carmen Bozic VRTX stock SEC Form 4 insiders trading
Carmen has made over 12 trades of the Vertex Pharmaceuticals stock since 2023, according to the Form 4 filled with the SEC. Most recently he sold 2,280 units of VRTX stock worth 1,086,990$ on 7 August 2024.
The largest trade he's ever made was selling 5,651 units of Vertex Pharmaceuticals stock on 31 October 2023 worth over 2,011,304$. On average, Carmen trades about 1,487 units every 11 days since 2020. As of 7 August 2024 he still owns at least 23,259 units of Vertex Pharmaceuticals stock.
You can see the complete history of Carmen Bozic stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Carmen Bozic biography
Dr. Carmen Bozic, M.D., is Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer of the Company. Dr. Bozic received her M.D. and completed her residency in Internal medicine at McGill University in Montreal, Canada, and then completed a fellowship in Pulmonary and Critical Care Medicine at Brigham and Women's Hospital in Boston. Since joining Vertex, she has been leading Clinical Development of the company's cystic fibrosis and alpha-1 antitrypsin deficiency programs, as well as leading Clinical Operations across the pipeline, among other areas. Prior to joining Vertex, Dr. Bozic spent more than 20 years at Biogen, including as Senior Vice President, Global Development. During her tenure at Biogen, she led multiple functions, including Global Clinical Development, Safety, Preclinical Safety, Regulatory, Clinical Operations and Biometrics.
What's Carmen Bozic's mailing address?
Carmen's mailing address filed with the SEC is C/O VERTEX PHARMACEUTICALS INCORPORATED, 50 NORTHERN AVENUE, BOSTON, MA, 02210.
Insiders trading at Vertex Pharmaceuticals
Over the last 21 years, insiders at Vertex Pharmaceuticals have traded over 934,925,905$ worth of Vertex Pharmaceuticals stock and bought 308,652 units worth 12,298,449$ . The most active insiders traders include Lloyd Carney、Jeffrey M Leiden、Joshua S Boger. On average, Vertex Pharmaceuticals executives and independent directors trade stock every 5 days with the average trade being worth of 4,747,875$. The most recent stock trade was executed by Jeffrey M Leiden on 30 August 2024, trading 3,784 units of VRTX stock currently worth 1,888,216$.
What does Vertex Pharmaceuticals do?
Vertex Pharmaceuticals is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry.
What does Vertex Pharmaceuticals's logo look like?
Complete history of Carmen Bozic stock trades at Vertex Pharmaceuticals
Vertex Pharmaceuticals executives and stock owners
Vertex Pharmaceuticals executives and other stock owners filed with the SEC include:
-
Jeffrey Leiden,
Executive Chairman of the Board -
Stuart Arbuckle,
Executive Vice President, Chief Commercial Officer -
Reshma Kewalramani,
President, Chief Executive Officer, Director -
Amit Sachdev,
Executive Vice President, Chief Regulatory Officer and Chief of Staff to the CEO -
David Altshuler,
Executive Vice President - Global Research, Chief Scientific Officer -
Michael Parini,
Executive Vice President, Chief Legal and Administrative Officer -
Dr. Reshma Kewalramani FASN, M.D.,
CEO, Pres & Director -
Charles Wagner,
Chief Financial Officer, Executive Vice President -
Paul Silva,
Senior Vice President, Controller -
Dr. Jeffrey Marc Leiden M.D., Ph.D.,
Exec. Chairman -
Stuart A. Arbuckle B.Sc.,
Exec. VP & COO -
Dr. David M. Altshuler,
Exec. VP of Global Research & Chief Scientific Officer -
Charles F. Wagner Jr.,
Exec. VP & CFO -
Bruce Sachs,
Co-Lead Independent Director -
Margaret McGlynn,
Independent Director -
Terrence Kearney,
Independent Director -
Sangeeta Bhatia,
Independent Director -
Yuchun Lee,
Independent Director -
William Young,
Independent Director -
Alan Garber,
Independent Director -
lloyd Carney,
Independent Director -
Michael Partridge,
Vice President - Investor Relations -
Diana McKenzie,
Independent Director -
Nia Tatsis,
Senior Vice President, Chief Regulatory Officer -
John Gray,
Senior Vice President, Genetic Therapies -
Gerald Bruce,
Executive Vice President, Commercial Operations -
Carmen Bozic,
Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer -
Joy Liu,
Sr. VP & Gen. Counsel -
Damian W. Wilmot Esq.,
Sr. VP, Chief Risk and Compliance Officer -
Mike Tirozzi,
SVP and Chief Information & Data Officer -
Kristen Ambrose,
Chief Accounting Officer & SVP of Accounting, Tax, Treasury, Strategic Sourcing & Corp. Services -
Joshua S Boger,
Chairman & CEO -
Elaine Ullian,
Director -
Ian F Smith,
SVP & CFO -
Jeffrey Chodakewitz,
SVP GMDA, CMO -
Thomas Graney,
Chief Financial Officer -
Michel Lagarde,
Director -
Wayne Joseph Riley,
Director -
Peter Mueller,
CSO & SVP Drug Discovery -
Thomas Connolly,
SVP, Human Resources -
Kenneth L Horton,
EVP & Chief Legal Officer -
Megan E Pace,
SVP, Corp. Communications -
Christiana Stamoulis,
SVP, Corp Strategy & Bus Devlp -
Matthew Emmens,
Director -
Lisa Kelly,
SVP, Human Resources -
Dennis L Winger,
Director -
Eugene Cordes,
Director -
Nancy Wysenski,
EVP & Chief Commercial Officer -
David T Howton,
SVP -
Kenneth S Boger,
SVP & General Counsel -
Kurt Graves,
EVP, Chief Commercial Officer -
John J Alam,
SVP, Drug Eval. & Appr. -
Stuart J Collinson,
Director -
Charles A Sanders,
Director -
Roger W Brimblecombe,
Director -
Freda C Lewis Hall,
EVP, Medicines Development -
Eve Elizabeth Slater,
Director -
Richard C Garrison,
SVP, Organizational Developmen -
Johanna Messina Power,
Controller -
Victor A Hartmann,
EVP, Strategic & Corp. Devlp. -
Eric Brandt,
Director -
Lynne H Brum,
VP, Corp. Comm.&Financial Plan -
Paul A Negulescu,
VP, Research -
John F Niblack,
Director -
Iain P M Buchanan,
VP, European Operations -
Vicki L Sato,
President -
N Anthony Coles,
SVP, Comm. Ops. -
Bastiano Sanna,
EVP, Cell & Genetic Therapies -
Joy Liu,
SVP, General Counsel -
Kristen Ambrose,
SVP & Chief Accounting Officer -
Suketu Upadhyay,
Director -
Jonathan Biller,
EVP and Chief Legal Officer -
Nancy Thornberry,
Director -
Edward Morrow Iii Atkinson,
EVP, Chief Technical Ops. Off. -
Jennifer Schneider,
Director